Group 1: New Stock Performance - The recent performance of new stocks on the Beijing Stock Exchange remains highly active, with the stock of Sanxie Electric rising by over 860% on its first day of trading, closing up 785.62%, marking the highest first-day increase of the year [1] - Aifenda also saw a first-day increase of 170.03%, with a single subscription yield exceeding 16,000 yuan [1] Group 2: Upcoming IPOs - This week, there are five new stocks available for subscription, including three from the Growth Enterprise Market, one from the Shenzhen Main Board, and one from the Beijing Stock Exchange [3] - The first stock available for subscription on September 15 is United Power, a leader in the new energy vehicle power system industry, collaborating with major automotive brands [1][5] Group 3: Financial Projections - United Power expects to achieve a net profit of 750 million to 900 million yuan in the first three quarters of 2025, representing a year-on-year growth of 31.05% to 57.26% [5] - The projected revenue for United Power in the same period is between 1.4 billion and 1.55 billion yuan, indicating a growth of 30.62% to 44.61% compared to the previous year [6] Group 4: Other Companies' Projections - Jianfa Zhixin anticipates a net profit of 200 million to 222 million yuan for the first three quarters of 2025, reflecting a growth of 30% to 40% [7] - Jin Hua New Materials expects a decline in revenue to 1.063 billion yuan for the full year 2025, down 14.25%, with a net profit of 199 million yuan, a decrease of 5.47% [9] - Rui Li Ke Mi forecasts a net profit of 196 million to 220 million yuan for the first three quarters of 2025, with a growth rate of 11.96% to 25.67% [10][11] - Yunhan Xincheng projects a net profit of 77 million to 80 million yuan for the first three quarters of 2025, with a growth of 38.71% to 44.11% [12][13]

Core Insights - Three companies, Jianfa Zhixin, United Power, and Jinhua New Materials, were listed on September 25, with Jianfa Zhixin being a national high-value medical device distributor, United Power focusing on new energy vehicle power systems, and Jinhua New Materials specializing in fine chemicals [1][3][5]. Group 1: Jianfa Zhixin - Jianfa Zhixin operates as a high-value medical device distributor, providing direct sales and distribution services, and offering centralized operation services for medical consumables [1][2]. - The company is a subsidiary of Xiamen Jianfa Group, with the Xiamen State-owned Assets Supervision and Administration Commission indirectly holding 51.02% of its shares [1][2]. - For 2024, Jianfa Zhixin's revenue is projected to be divided into three segments: direct sales (11.032 billion, 61.69%), distribution (6.738 billion, 37.68%), and service (112 million, 0.63%) [1]. Group 2: United Power - United Power, established in 2016, is a provider of power systems for new energy vehicles, having been spun off from the industrial automation giant, Inovance Technology [3][4]. - The company is positioned as a leader in the new energy vehicle power system industry, participating in over 20 national standard formulations and providing solutions for over 40 vehicle manufacturers [4][5]. - In 2024, United Power is expected to deliver over 4.5 million power system products, collaborating with major domestic and international automotive brands [4]. Group 3: Jinhua New Materials - Jinhua New Materials specializes in the research, production, and sales of ketoxime series fine chemicals, being a leader in the domestic silane crosslinking agent market [5][6]. - The company's market share for silane crosslinking agents is projected to grow from 27.85% in 2022 to 38.16% in 2024 [6]. - Jinhua New Materials has received multiple honors, including being recognized as a national "little giant" enterprise and participating in the formulation of several national industry standards [6][7].

一、网上申购情况 保荐人（主承销商）根据深交所提供的数据，对本次网上发行的申购情况进行了统计，本次网上发行有 效申购户数为 13,472,178 户，有效申购股数为 105,070,116,500 股，配号总数为 210,140,233 个，配号起 始号码为000000000001， 截止号码为000210140233。 根据《上海建发致新医疗科技集团股份有限公司首次公开发行股票并在创业 板上市发行公告》公布的 回拨机制，由于网上初步有效申购倍数为10,392.17808 倍，高于100倍，发行人和保荐人（主承销商） 决定启动回拨机制，将扣除最终 战略配售数量后本次公开发行股票数量的20%（向上取整至500股的整 数倍，即 10,743,000 股）由网下回拨至网上。 回拨后，网下最终发行数量为32,860,785股， 约占扣除最终战略配售数量后本次发行数量的 61.18%； 网上最终发行数量为 20,853,500 股，约占扣除最终战略配售数量后本次发行数量的38.82%。回拨后本 次网上发行的中签率为0.0198472227%，申购倍数为5,038.48834倍。 二、回拨机制实施、发行结构及网上发行中签 ...

Core Viewpoint - Jianfa Zhixin (301584.SZ) is set to go public on the ChiNext board with an issue price of 7.05 yuan per share and a price-to-earnings ratio of 13.01 times, indicating strong growth potential in the medical device distribution sector [1] Group 1: Business Overview - Jianfa Zhixin primarily engages in direct sales and distribution of medical devices, providing centralized operation services for medical consumables (SPD) to hospitals, and holds a significant market position in the medical device distribution field [1] - The company has established a nationwide distribution network and maintains long-term partnerships with over 100 well-known domestic and international medical device manufacturers [2] - The company has achieved full coverage of the distribution industry chain, connecting manufacturers and end medical institutions, and offers a wide range of direct sales services to over 3,300 medical institutions across 31 provinces and municipalities [1][2] Group 2: Financial Performance - Jianfa Zhixin's projected revenue for 2024 is 17.923 billion yuan, with a net profit of 274 million yuan, and a five-year compound annual growth rate (CAGR) of over 20% in revenue [1] - The revenue composition indicates a strong focus on high-value consumables, with vascular intervention business generating 9.967 billion yuan and surgical medical devices contributing 3.847 billion yuan, totaling over 13.8 billion yuan [2][3] Group 3: Market Position and Growth Potential - The high-value medical consumables market is expected to grow significantly, driven by factors such as an aging population and improved healthcare standards, with the market share projected to reach 16% in 2024 [3][4] - Jianfa Zhixin aims to expand its sales scale in various medical device sectors, including IVD, surgical, oral, and ophthalmic products, while consolidating its high-value consumables business [4] Group 4: Innovation in Business Model - The company has rapidly developed its SPD business model, managing the operation and logistics of medical consumables within hospitals while allowing hospitals to retain selection and procurement rights [5] - By the end of 2024, Jianfa Zhixin has signed contracts with 60 hospitals for its SPD services, managing over 10 billion yuan in medical consumables [5][6] - The SPD model enhances the efficiency of medical consumables management and reduces costs for healthcare institutions, while also creating synergies with the company's direct sales and distribution businesses [6]

Core Viewpoint - The company is a national high-value medical device distributor, primarily engaged in direct sales and distribution of medical devices, providing centralized operation services for medical consumables to hospitals [2] Summary by Category Company Overview - The company started its subscription on September 16, with an issue price of 7.05 yuan per share, a pre-issue market value of 25.25 billion yuan, and an issue price-to-earnings (P/E) ratio of 13.29 times, compared to the industry average P/E ratio of 25.73 times [2] Financial Performance - Revenue projections from 2022 to 2024 are 11.88 billion, 15.44 billion, and 17.92 billion yuan, respectively, with a year-on-year growth of 16.06% in 2024 [2] - Net profit for the same period is projected to be 189.2 million, 226.9 million, and 273.8 million yuan, with a year-on-year growth of 20.68% in 2024 [2] - For the third quarter of 2025, the company expects revenue growth of 10% to 15% year-on-year, and net profit growth of 30% to 40%, with non-recurring net profit growth of 26% to 40% [2] Valuation Comparison - In comparison with peer companies, the company's dynamic and static P/E ratios indicate a relatively low valuation, with a dynamic P/E of 10.65 and a static P/E of 13.29 [3] - The company has a total market value of 29.71 billion yuan and a circulating market value of 4.46 billion yuan, with an issue price considered inexpensive [3] Market Sentiment - The company is state-owned, with a 51% shareholding by state-owned enterprises, and the expected price increase on the first day of trading is between 248.1% and 413.5% [3]

Core Viewpoint - The company Jianfa Zhixin (301584.SZ) has initiated its subscription with an issue price of 7.05 yuan per share and a price-to-earnings ratio of 13.29 times, positioning itself as a national high-value medical device distributor [1] Company Overview - Jianfa Zhixin operates primarily in the direct sales and distribution of medical devices, providing centralized operation services for medical consumables (SPD) to hospitals across China [1] - The company plays a crucial role in the medical device supply chain, linking manufacturers, distributors, and end medical institutions [1] - It offers direct sales services to over 3,300 medical institutions across 31 provinces, municipalities, and autonomous regions in China, with a wide range of product specifications [1] - The company has established a nationwide distribution network, focusing on high-value interventional products, and maintains long-term partnerships with over 100 well-known domestic and international medical device manufacturers [1] Industry Context - The medical device distribution industry is evolving towards channel integration and flattening due to policies like centralized procurement and the "two-invoice system" [2] - The company is leveraging information technology in traditional distribution operations to enhance service capabilities for upstream and downstream clients [2] - Technological innovations include the application of information management and IoT technologies to optimize supply chain efficiency and reduce costs [2] - The company has developed a digital supply chain management system for medical devices, addressing issues like "one product, multiple codes" through unique identification and management [2] Financial Performance - The company reported revenues of approximately 11.882 billion yuan, 15.443 billion yuan, and 17.923 billion yuan for the years 2022, 2023, and 2024, respectively [3] - Net profits for the same years were approximately 189 million yuan, 227 million yuan, and 274 million yuan [3] - Total assets as of December 31 for 2022, 2023, and 2024 were approximately 90.57 billion yuan, 111.71 billion yuan, and 131.12 billion yuan, respectively [3] - The company's equity attributable to shareholders increased from approximately 10.497 billion yuan in 2022 to 14.812 billion yuan in 2024 [3] - The asset-liability ratio for the parent company rose from 73.92% in 2022 to 79.32% in 2024, while the consolidated asset-liability ratio showed a slight decrease from 87.39% in 2022 to 86.45% in 2024 [3]

Summary of Key Points Core Viewpoint - Shanghai Jianda Zhixin Medical Technology Group Co., Ltd. is set to list its ordinary shares on the Shenzhen Stock Exchange's ChiNext board on September 25, 2025, following approval from the Shenzhen Stock Exchange [1]. Company Overview - Stock Name: Jianda Zhixin - Stock Code: 301584 - Total Shares Post-IPO: 421,288,509 shares - Number of New Shares Issued: 63,193,277 shares, with no existing shares being transferred [5]. Industry Context - The company belongs to the "F51 Wholesale Industry" as per the classification by the China Association of Listed Companies [3]. - As of September 10, 2025, the average static P/E ratio for the "F51 Wholesale Industry" was 25.73 times [3]. Financial Metrics - The IPO price is set at 7.05 RMB per share, which corresponds to a diluted P/E ratio of 13.29 times based on the lower of the 2024 net profit attributable to the parent company, excluding non-recurring gains and losses [3]. - This P/E ratio is lower than the industry average of 25.73 times but higher than the average P/E ratio of comparable listed companies, which is 11.27 times, indicating a premium of approximately 17.92% [3]. Market Risks - The ChiNext board is characterized by higher investment risks, including unstable performance, operational risks, and a greater likelihood of delisting [3]. - Investors are advised to be aware of the potential for stock price declines and to assess the reasonableness of the IPO pricing carefully [3].

Group 1: Company Overview - Jianfa Zhixin (301584.SZ) is a national high-value medical device distributor, primarily engaged in direct sales and distribution of medical devices, providing centralized operation services for medical consumables to hospitals [1][4] - The company is a subsidiary of Xiamen Jianfa Group, with the State-owned Assets Supervision and Administration Commission of Xiamen City indirectly holding 51.02% of its shares [4] - In 2024, Jianfa Zhixin's revenue is expected to be divided into three main segments: direct sales (110.32 billion CNY, 61.69%), distribution (67.38 billion CNY, 37.68%), and service (1.12 billion CNY, 0.63%) [4] Group 2: Financial Performance - Jianfa Zhixin's initial public offering (IPO) price was 7.05 CNY per share, with a market capitalization of 29.70 billion CNY and an issuance price-to-earnings ratio of 13.29 [2] - The company has a high asset-liability ratio, with figures of 87.39%, 87.19%, and 86.45% from 2022 to 2024, indicating a capital-intensive business model [5] Group 3: Fundraising and Investment Plans - Jianfa Zhixin plans to allocate raised funds as follows: 1.40 billion CNY (28.94%) for information system upgrades, 1.04 billion CNY (21.49%) for centralized operation services, and 2.40 billion CNY (49.56%) for working capital [3] Group 4: Joint Power Company Overview - United Power (301656.SZ) was established in 2016 as a spin-off from the A-share giant Huichuan Technology, focusing on providing power systems for new energy vehicles [6][10] - The company is a leader in the new energy vehicle power system industry, participating in over 20 national standard formulations and providing solutions for more than 40 vehicle manufacturers [10] Group 5: Financial Performance of United Power - United Power's IPO price was 12.48 CNY per share, with a market capitalization of 300.1 billion CNY and an issuance price-to-earnings ratio of 32.87 [6] - The company reported accounts receivable values of 18.5 billion CNY, 36.1 billion CNY, and 56.8 billion CNY from 2022 to 2024, representing 20.37%, 29.38%, and 31.45% of total assets respectively [11] Group 6: Fundraising and Investment Plans of United Power - United Power intends to invest raised funds as follows: 26.12 billion CNY (53.77%) for core component production, 13.23 billion CNY (27.24%) for R&D center construction, and 8.00 billion CNY (16.47%) for working capital [8][9] Group 7: Jin Hua New Material Company Overview - Jin Hua New Material focuses on the research, production, and sales of ketoxime series fine chemicals, being a leader in the domestic silane crosslinking agent and hydroxylamine salt sectors [12][16] - The company has a market share of 27.85%, 31.60%, and 38.16% in silane crosslinking agents from 2022 to 2024 [16] Group 8: Financial Performance of Jin Hua New Material - The IPO price for Jin Hua New Material was 18.15 CNY per share, with an issuance price-to-earnings ratio of 11.52 [13] - The company has highlighted potential risks related to market demand fluctuations in downstream industries, particularly in real estate and photovoltaic sectors [17]

Group 1 - The listing ceremony for Shanghai C&D INNOSTIC Medical Technology Group Co., Ltd. is scheduled for September 25, 2025, from 08:55 to 09:30, and will be live-streamed by Quanjing Roadshow [1][3] - Shanghai C&D INNOSTIC, established in 2010 and headquartered in Shanghai, is a member of the C&D Group and operates as a national medical device distributor [3] - The company engages in direct sales and distribution of medical devices and provides centralized operation services for medical consumables to hospitals, maintaining long-term partnerships with over 100 well-known domestic and international high-value medical device manufacturers [3] Group 2 - The agenda for the listing ceremony includes watching a promotional video, speeches from leaders, ringing the opening bell, and a group photo session [3]

上海建发致新医疗科技集团 股份有限公司 （上海市杨浦区杨树浦路 288 号 9 层） 首次公开发行股票并在创业板上市 之 上市公告书 保荐人（主承销商） （广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座） 二〇二五年九月 股票简称：建发致新 股票代码：301584 上海建发致新医疗科技集团股份有限公司 上市公告书 特别提示 上海建发致新医疗科技集团股份有限公司（以下简称"建发致新"、"本公司"、 "公司"或"发行人"）股票将于 2025 年 9 月 25 日在深圳证券交易所上市。 创业板公司具有业绩不稳定、经营风险高、退市风险高等特点，投资者面临较大的 市场风险。投资者应充分了解创业板市场的投资风险及本公司所披露的风险因素，审慎 作出投资决定。 本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素，在新股上市 初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 如无特别说明，本上市公告书中的简称或名词释义与《上海建发致新医疗科技集团 股份有限公司首次公开发行股票并在创业板上市招股说明书》（以下简称"招股说明书"） 中的相同。如本上市公告书中合计数与各加数直接相加之和在尾数上存在差异，系由于 ...